PRESS STATEMENTS

07.24.2013

Pfizer Statement on PhRMA-EFPIA Principles for Responsible Clinical Trial Data Sharing

07.02.2013

Pfizer Mourns Loss of Prominent Leader and Respected Board Member

03.19.2013

Pfizer Responds to New York Times Article on NIH Policy

03.18.2013

Original Statement Provided to New York Times

03.15.2013

Pfizer Response To Global Consensus Statement On Menopausal Hormone Therapy

03.12.2013

Zithromax (azithromycin) FDA Drug Safety Communication

11.29.2012

Pfizer Chairman and Chief Executive Officer Ian Read Issues Statement on White House Meeting

10.24.2012

Pfizer Donates Vials of Factor IX to the World Federation of Hemophilia to Help Developing Countries

10.03.2012

Findings from the Kronos Early Estrogen Prevention Study (KEEPS), presented today at The North American Menopause Society (NAMS) Annual Meeting in Orlando, Fla.

08.30.2012

The U.S. Food and Drug Administration issued a Drug Safety Communication on Revatio®

07.30.2012

Pfizer Helpful Answers mourns the loss of actor Lupe Ontiveros

07.09.2012

Ongoing Analyses have Helped Re-evaluate Benefit-Risk Profile of Hormone Therapy for Appropriate Menopausal Women

03.15.2012

Pfizer Response To Ongoing Evaluation Of Hormone Therapy And Breast Cancer, And What It Means For Menopausal Women Who Have Had A Hysterectomy

01.30.2012

Pfizer Joins Innovative Partnership to Eliminate or Control 10 Neglected Tropical Diseases by 2020

11.30.2011

Pfizer Statement Responding to Questions on Voluntary Lipitor Contracting Programs

11.17.2011

Pfizer applauds U.S. Sens. Pat Leahy (VT) and Charles Grassley (IA) and U.S. Reps. Patrick Meehan (PA) and Linda Sanchez (CA) for introducing the "Counterfeit Drug Penalty Enhancement Act of 2011."

11.16.2011

Pfizer announced that the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC)

11.02.2011

Pfizer Responds to Analysis in PLoS One, an Online Publication of the Public Library of Science

10.06.2011

Pfizer Statement Regarding Lyrica Epilepsty

09.08.2011

Pfizer Receives Complete Response Letter From FDA For Moderate-To-Severe Vasomotor Symptoms (VMS) Indication For Pristiq® (desvenlafaxine) Extended Release Tablets.